Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Axiron Sales Back on Track; New Acrux CEO announced: Fair Value Unchanged

      Commentary

      Thu, 24 Jul 2014

      Axiron net sales, as announced by Eli Lilly , for the quarter ended 30 June 2014 totalled USD 47 ..... single-product focus, and limited control over sales under the Eli Lilly agreement, and reiterate our very high uncertainty rating

    2. UPDATE 3-Lilly beats forecasts, vows to remain independent

      Headlines

      Thu, 24 Jul 2014

      July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings...

    3. BRIEF-Lilly says would not pursue tax inversions as "primary driver" of potential deals

      Headlines

      Thu, 24 Jul 2014

      July 24 (Reuters) - Eli Lilly and Co : * CFO, in conference call with investors, says company would not pursue tax inversions as "primary driver" of any

    4. Lilly lowers guidance after Q2 results

      Headlines

      Thu, 24 Jul 2014

      Eli Lilly (NYSE: LLY ) Q2 results : Total Revenue: $4,935.6M (-16.4%), Animal Health: $601.2M (+5.7%); COGS

    5. Patent Losses Cause a 42% Earnings Drop for Eli Lilly in 2Q, but Pipeline Sets Up Growth in 2015

      Commentary

      Thu, 24 Jul 2014

      Eli Lilly reported second-quarter results that ran slightly ahead of both our expectations and those of consensus. While Lilly is facing

    6. Lilly beats forecasts, helped by cost controls

      Headlines

      Thu, 24 Jul 2014

      July 24 (Reuters) - Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but overall results beat forecasts, helped by cost controls.

    7. Eli Lilly beats by $0.03, beats on revenue

      Headlines

      Thu, 24 Jul 2014

      Eli Lilly (NYSE: LLY ): Q2 EPS of $0.68 beats by $0.03 . Revenue of $4.94B (-16.7% Y/Y) beats by $60M . Press Release Post your comment!

    8. Does The Eli Lilly Whisper Number Indicate Investor Confidence?

      Headlines

      Wed, 23 Jul 2014

      By WhisperNumber : Eli Lilly and Company (NYSE: LLY ) is expected to report earnings on Thursday ..... the analysts' estimate and showing no confidence from investors. Eli Lilly has a 74% positive surprise history (having topped the whisper in

    9. Lilly and Canadian government spar over drug patents

      Headlines

      Tue, 15 Jul 2014

      Many industry observers are watching the IP-related dispute between Eli Lilly ( LLY -0.4% ) and the Canadian government. Several years ago, Canadian courts invalidated Lilly's patents on its ADHD drug

    10. Data analysis finds cognitive deficits precede functional deficits in Alzheimer's

      Headlines

      Tue, 15 Jul 2014

      A dataset analysis by researchers at Eli Lilly (NYSE: LLY ) evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease

    « Prev12345Next »
    Content Partners